NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

August 29, 2024

Study Completion Date

November 21, 2024

Conditions

Advanced Solid TumorMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial CarcinomaCervical CancerHepatoCellular CarcinomaEsophageal Squamous Cell CarcinomaMerkel Cell CarcinomaSmall-cell Lung CancerMesotheliomaPD-L1 Amplified Tumor (9p24.1)Nasopharyngeal Carcinoma

Interventions

DRUG

INCB099280

INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle

Trial Locations (21)

13385

Chu Hopital de La Timone, Marseille

15232

Upmc Cancercenter, Pittsburgh

33076

Institut Bergonie, Bordeaux

35042

Centre Eugene Marquis, Rennes

48202

Henry Ford Hospital, Detroit

49000

Institut de Cancerologie de L Ouest - Site Paul Papin, Angers

77030

Md Anderson Cancer Center, Houston

94800

Institut Gustave Roussy, Villejuif

98195

University of Washington, Seattle

02215

Dana Farber Cancer Institute, Boston

02050

Chris Obrien Lifehouse, Camperdown

03084

Austin Hospital, Heidelberg

03004

Nucleus Network Pty Ltd, Melbourne

06009

Linear Clinical Research, Nedlands

01200

Cliniques Universitaires Ucl Saint-Luc, Brussels

B-1070

Institut Jules Bordet Clinical Trials Conduct Unit, Brussels

02650

Universitair Ziekenhuis Antwerpen (Uza), Edegem

09000

Ghent University Hospital, Ghent

03000

Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven

277-8577

National Cancer Center Hospital East, Chiba

104-0045

National Cancer Center Hospital, Tokyo